ET
ACAD icon

Entropy Technologies’s Acadia Pharmaceuticals ACAD Stock Holding History

Entropy Technologies’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,060
Closed -$536K – 931
2026
Q1 		$536K Buy
24,060
+11,264
+88% +$269K 0.02% 571
2025
Q4 		$342K Buy
+12,796
New +$306K 0.02% 671
2024
Q3 		– Sell
-10,881
Closed -$177K – 690
2024
Q2 		$177K Buy
+10,881
New +$176K 0.02% 606

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Entropy Technologies's ACAD Position: Q2 2026 in Review

Entropy Technologies sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 24,060 shares — an estimated $536K sold.

Entropy Technologies first reported a position in ACAD in Q2 2024 and held it in 3 quarters. The position peaked at $536K in Q1 2026. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Entropy Technologies reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Entropy Technologies sold 24,060 Acadia Pharmaceuticals shares in Q2 2026, an estimated $536K.
  • Entropy Technologies first reported a position in Acadia Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Entropy Technologies's Acadia Pharmaceuticals position peaked at $536K in Q1 2026.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.